<DOC>
	<DOCNO>NCT00518466</DOCNO>
	<brief_summary>The primary objective study describe single- multiple-dose pharmacokinetic profile two novel formulation topiramate commercially available immediate release topiramate , dose immediate release phentermine .</brief_summary>
	<brief_title>Pharmacokinetic Comparison Multiple Formulations Topiramate Phentermine Obese Adults</brief_title>
	<detailed_description />
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Phentermine</mesh_term>
	<criteria>Obese adult Body mass index 30.0 42.0 kg/m2 ( inclusive ) Medically healthy clinically significant result screen exams History presence significant cardiovascular , pulmonary , hepatic , renal , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease History glaucoma increase intraocular pressure History kidney stone Cholelithiasis cholecystitis within 6 month Cardiovascular event within 6 month Obesity know genetic endocrine origin Recent weight instability Use Very Low Calorie diet participation organize weight loss program within 3 month Systolic blood pressure &gt; 150 diastolic &gt; 95 mm Hg Positive urine drug alcohol screen Positive serology HIV , HBV , HCV History alcoholism drug abuse History significant psychiatric disease , current depression moderate great severity , history suicidal ideation Hypersensitivity study drug relate compound Use prescription OTC medication hormonal contraceptive within 14 day prior first dose study drug Blood donation significant blood loss within 56 day plasma donation within 7 day prior first dose study drug Women pregnant lactate Hemoglobin &lt; 12 g/dL Use tobacco nicotinecontaining product within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Obesity</keyword>
</DOC>